Provided by Tiger Fintech (Singapore) Pte. Ltd.

iHuman

2.80
-0.0826-2.87%
Pre-market: 2.980.1800+6.43%08:14 EDT
Volume:16.97K
Turnover:48.58K
Market Cap:144.26M
PE:10.69
High:3.01
Open:2.88
Low:2.70
Close:2.88
52wk High:3.60
52wk Low:1.47
Shares:51.52M
Float Shares:14.72M
Volume Ratio:1.12
T/O Rate:0.12%
Dividend:0.00
Dividend Rate:0.04%
EPS(TTM):0.2619
EPS(LYR):0.2578
ROE:11.26%
ROA:3.46%
PB:1.09
PE(LYR):10.86

Loading ...

Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference

GlobeNewswire
·
Apr 09

Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory

Insider Monkey
·
Apr 04

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

GlobeNewswire
·
Apr 03

Do Its Financials Have Any Role To Play In Driving iHuman Inc.'s (NYSE:IH) Stock Up Recently?

Simply Wall St.
·
Mar 27

Stock Track | iHuman Stock Plummets 5.79% Following Disappointing Q4 and Full Year 2024 Results

Stock Track
·
Mar 25

Stock Track | iHuman Stock Plummets 5.79% as Q4 Revenue and Profit Decline

Stock Track
·
Mar 25

Press Release: iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

Dow Jones
·
Mar 25

CNH Industrial says precision technology helping farmers tackle water scarcity

TIPRANKS
·
Mar 24

Press Release: Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

Dow Jones
·
Mar 24

HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Zacks
·
Mar 20

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

GlobeNewswire
·
Mar 12

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
Mar 11

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

GlobeNewswire
·
Mar 07

Stock Track | iHuman Stock Soars 6.54% as Lumryz Sales Surge and 2025 Guidance Reaffirmed

Stock Track
·
Mar 03

Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
Mar 03

The recent 11% gain must have brightened Top Key Executive Yufeng Chi's week, iHuman Inc.'s (NYSE:IH) most bullish insider

Simply Wall St.
·
Feb 28